BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Phase I study designed to determine the safety and tolerability of a single dose of BIIB023
administered intravenously versus placebo to subjects with RA.